ANEB — Anebulo Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Anebulo Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Anebulo Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Anebulo Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Anebulo Pharmaceuticals Announces New CEO
Brief: Anebulo Pharmaceuticals Announces Appointment Of Bimal Shah To Its Board Of Directors
Brief: Anebulo Pharmaceuticals Inc Terminated Without Cause Employment Of Simon Allen, Co's CEO
Anebulo Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Anebulo Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Anebulo Says On Aug 29, Potrero Hill Advisors Provided Notice To Terminate Certain Master Services Agreement Between Co, Potrero
Brief: FDA Gives Positive Feedback For Anebulo's Aneb-001
Brief: Anebulo Pharmaceuticals Inc Reports Quarterly Loss Per Share Of $0.11
Brief: Anebulo Pharmaceuticals Reports Q2 Loss Of $0.15 Per Share
Brief: Anebulo Pharma Reports $0.15 Per Share Loss In Second Quarter
Brief: Anebulo Pharmaceuticals Announces Completion Of Dosing, Preliminary Data From Part B Of Its Phase 2 Study Of ANEB-001
U.S. STOCKS ON THE MOVE-Digital World Acquisition, Carnival, Crypto stocks
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Chegg, Li Auto
Anebulo Pharma up on cannabis intoxication drug trial data
Brief: Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
Brief: Anebulo Pharmaceuticals Announces Positive Interim Data For Aneb-001 From Part B Of Its Phase 2 Clinical Trial For Acute Cannabinoid Intoxication